A new level of insight for anti-VEGF therapy planning for neovascular age-related macular degeneration (nAMD) patients is expected with Heidelberg and deepeye Medical’s collaboration, Deepeye Therapy Planning Support (TPS).
Developed from insights gathered from more than one million retinal images from thousands of patients across 200 centres over 10 years, Deepeye TPS is designed to assist eyecare specialists in making more informed treatment decisions, said Manuel Opitz, Deepeye Medical CEO. “Our AI mimics a proven clinical method of double reading that is widely established in radiology and mammography, to empower ophthalmologists to personalise treatment faster, driving outcomes and adherence. With Heidelberg AppWay we are set to empower retina specialists with data-driven insights to optimise therapy planning. Better patient outcomes and economically viable practices are the objective.”
Currently awaiting full CE marking, Deepeye TPS will be available on the Heidelberg AppWay AI Marketplace and is compatible with Heidelberg’s Spectralis and Heyex 2 devices.
